Amyris, Inc.

{{Short description|American biotechnology company}}

{{Infobox company

| name = Amyris, Inc.

| logo = Wiki-Amyris Purple.png

| type = Private

| foundation = {{start date and age|2003}}

| location = Emeryville, California, U.S.

| industry = Synthetic biology, advanced precision fermentation

| key_people = {{ubl|Kathy Fortmann (CEO)| Adam Blaziak (Chief Manufacturing & Supply Chain Officer)|Doris Choi (Gen.Counsel & Secretary)}}

| homepage = {{URL|http://amyris.com/}}

| num_employees = 500+ (2025)

}}

Amyris, Inc., founded in 2003, is a synthetic biotechnology company headquartered in Emeryville, California. Amyris serves the specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals markets.{{cite news |title=Amyris Inc - Company Profile |url=https://www.bloomberg.com/profile/company/AMRS:US |work=Bloomberg.com |language=en}}

In January 2016, the company received an investment from the Bill & Melinda Gates Foundation's Strategic Innovation Fund to support the development of antimalarial medication based on semi-synthetic artemisinin.{{Cite web |title=Amyris |url=https://sif.gatesfoundation.org/investments/amyris/ |url-status=live |archive-url=https://web.archive.org/web/20231224201143/https://sif.gatesfoundation.org/investments/amyris/ |archive-date=2023-12-24 |access-date=2023-12-24 |website=Bill & Melinda Gates Foundation Strategic Innovation Fund |language=en-US}} In April 2019, the company raised $34-million in private placement of its common stock and warrants.

In 2020, Amyris received Bonsucro's Chain of Custody Certification, ensuring that the sustainability claims along the sugarcane supply chain are traceable from farmer to end user.{{cite news |last1=Staff |title=Amyris' Sugarcane Is Traceable |url=https://www.happi.com/contents/view_breaking-news/2020-12-28/amyris-sugarcane-is-traceable/ |work=HAPPI}} During the COVID-19 pandemic, the company collaborated with the Infectious Disease Research Institute (IDRI) to advance a novel ribonucleic acid (RNA) vaccine platform, including accelerating the development of a COVID-19 vaccine.{{cite news |date=2020-10-20 |title=Amyris and The Infectious Disease Research Institute Enter into Exclusive License for Novel RNA Vaccine Platform, Beginning with COVID-19 Vaccine |language=en |work=Cision |url=https://www.prnewswire.com/news-releases/amyris-and-the-infectious-disease-research-institute-enter-into-exclusive-license-for-novel-rna-vaccine-platform-beginning-with-covid-19-vaccine-301157638.html |url-status=live |archive-url=https://web.archive.org/web/20231224200907/https://www.prnewswire.com/news-releases/amyris-and-the-infectious-disease-research-institute-enter-into-exclusive-license-for-novel-rna-vaccine-platform-beginning-with-covid-19-vaccine-301157638.html |archive-date=2023-12-24}}

On August 9, 2023, Amyris filed for Chapter 11 bankruptcy protection and announced it will shut down its consumer brands amongst selling itself.{{Cite web |url=https://news.bloomberglaw.com/bankruptcy-law/amyris-files-for-chapter-11-bankruptcy-protect-in-delaware?context=search&index=0 |title=Amyris files for Chapter 11 bankruptcy protection in Delaware |date=August 9, 2023 |access-date=August 10, 2023 |website=Bloomberg Law |language=en}} The company was delisted from Nasdaq and added to the OTC Markets. On May 7, 2024, the company emerged from bankruptcy. A new CEO, Kathy Fortmann, was installed and is today at the helm of the company where she is leading the 2030 strategy, which is focused on B2B customers.